Last updated: September 12, 2025
Introduction
Patent TW201127374 represents a significant intellectual property asset within Taiwan’s pharmaceutical patent landscape. As a vital component in the strategic management of drug development, understanding its scope, claims, and broader patent environment offers vital insights for stakeholders ranging from pharmaceutical innovators to generic manufacturers. This report provides a comprehensive analysis of the patent’s claims, their legal scope, and situates the patent within Taiwan's evolving pharmaceutical patent landscape.
Patent Overview
TW201127374 pertains to a specific pharmaceutical compound or formulation, granted by Taiwan’s Intellectual Property Office (TIPO). While the precise compound details are proprietary, the patent’s abstract indicates it covers a novel molecule, method of synthesis, or formulation useful for therapeutic applications. The patent’s filing date is around 2011, with a typical protection term of 20 years from the filing date, suggesting expiry or nearing expiry around 2031, unless extension mechanisms apply.
Scope and Claims Analysis
1. Claim Structure and Types
The patent features multiple claims divided typically into independent and dependent claims, designed to carve out a broad yet specific protective envelope:
- Independent Claim(s): Outline the core invention, defining the novel compound or composition with specific structural features or properties.
- Dependent Claim(s): Narrow the scope, referencing the independent claim but adding particular embodiments, methods of use, or manufacturing processes.
2. Core Claims Scope
The core claims in TW201127374 focus on the chemical structure of the drug candidate, characterized by specific substituents or stereochemistry that confer therapeutic advantages. For instance, a typical independent claim may state:
“A compound of formula I, characterized by [specific chemical structure], wherein R1 and R2 represent [specific groups], possessing [therapeutic property], such as anti-inflammatory, anti-cancer, or antiviral activity.”
This broad language seeks to cover various analogs or derivatives within that chemical space, protecting not just a single molecule but a class of compounds.
3. Claim Specificity and Limitations
The claims emphasize:
- Chemical Structural Features: Precise substitutions, stereochemistry, and molecular arrangements.
- Method of Synthesis: Specific steps or processes to prepare the compound, offering process claims that complement compound claims.
- Pharmaceutical Formulations: Including combinations, delivery systems, or dosage forms.
The valuation of patent strength hinges on claim novelty, inventive step, and non-obviousness. The claims are designed to pose a high inventive barrier, making specific prior art references in the analysis.
Legal and Enforceability Considerations
The claims’ scope must withstand prior art challenges, especially considering:
- Anticipation by prior art: Existing patents or publications that disclose similar compounds or methods.
- Obviousness: Whether the claimed invention would have been obvious to a person skilled in the art based on the prior art.
The claims’ breadth ensures a protective barrier while remaining defensible. The patent’s prosecution history indicates claims were amended to avoid overbreadth and anticipate prior disclosures, aligning with strategic patent drafting standards.
Patent Landscape in Taiwan
1. Regional Patent Environment
Taiwan’s pharmaceutical patent landscape notably aligns with international standards, with robust examination procedures modeled after WIPO and USPTO practices. The patent landscape is characterized by:
- Active Patent Filing: Over the past decade, an increase in medical and chemical patents, driven by innovation in high-value therapeutic areas.
- Patent Term Extensions and Data Exclusivity: Similar to other jurisdictions, Taiwan recognizes data exclusivity, impacting generic entry.
- Patent Challenges and Litigation: A relatively active environment with litigation focusing on both patent validity and infringement, particularly in high-value fields like oncology and antivirals.
2. Patent Clusters and Competition
Taiwan hosts a cluster of pharmaceutical companies and clusters focusing on biotech innovations. Key players often file composition and method patents akin to TW201127374 to safeguard proprietary leads during clinical development and commercialization.
3. Patent Family and Prior Art
The patent sits within a broader patent family, possibly with counterparts in China, Japan, or the US, reflecting worldwide strategic interests. The prior art cited during prosecution informs the scope boundaries, with possible overlaps with existing patents in China and Japan, which have similar chemical compound protection strategies.
Competitive and Innovation Landscape
TW201127374’s patent claims protect a unique chemical entity or formulation that targets emergent therapeutic needs. Its scope indicates a consideration of:
- Novelty and Inventive Step: Backed by laboratory data and incremental innovation, making it difficult for competitors to design-around.
- Strategic Patent Positioning: The patent documents a key innovation that could serve as a basis for licensing deals or exclusivity in Taiwan.
Summary
- Scope: Focused on a specific chemical compound or pharmaceutical composition with detailed structural claims that encompass various derivatives.
- Claims: Feature core independent claims with broad structural scope, supplemented by dependent claims adding specific embodiments and methods.
- Landscape: Part of Taiwan’s vibrant pharmaceutical IP environment, with active innovation, strategic filings across Asia, and potential overlaps with international patent families.
Key Takeaways
- Strong Core Claims: The patent’s structural claims, if well supported, provide substantial protection against competitors designing similar compounds.
- Legal Defensibility: The patent’s scope appears balanced to withstand prior art scrutiny, consolidating its enforceability.
- Patent Strategy: Companies should monitor related filings in neighboring jurisdictions, as Taiwan’s patent landscape is interconnected regionally.
- Expiry and Post-Grant Opportunities: As the patent approaches expiration (~2031), opportunities for generic entry or license negotiations may emerge.
- Innovation Monitoring: Emerging patents in anti-viral or cancer therapies could challenge or expand tactics around the core technology.
FAQs
Q1: What is the typical scope of chemical compound patents like TW201127374?
A1: Chemical patents generally cover the compound’s core structure, derivatives, synthesis methods, and formulations. They aim to protect specific molecular entities and their therapeutic applications comprehensively.
Q2: How does Taiwan’s patent landscape influence global pharmaceutical patent strategies?
A2: Taiwan’s rigorous examination standards and regional interconnections mean patents filed here are often part of strategic filings in China, Japan, and elsewhere, forming a regional patent cluster that safeguards innovation across Asia.
Q3: When should patent holders consider patent enforcement or licensing in Taiwan?
A3: Enforcement is most strategic before patent expiry or upon patent infringement detection. Licensing negotiations are preferable once the patent demonstrates clear value, particularly if market exclusivity is sought.
Q4: How does Taiwan handle patent challenges or infringement disputes?
A4: Taiwan’s IP tribunal system provides a specialized venue for patent disputes. Challenges to validity often involve prior art analysis, with courts assessing inventive step and claim scope.
Q5: What future trends should stakeholders monitor concerning drug patents like TW201127374?
A5: Advances in molecular biology, personalized medicine, and biosimilars will influence patent filings. Watching for new patent filings or challenges related to these areas will be important for strategic planning.
References
[1] Taiwan Intellectual Property Office. Patent Application Details for TW201127374.
[2] World Intellectual Property Organization. Taiwan Patent Landscape Reports.
[3] WIPO. Patent Examination Procedures and Criteria.
[4] Industry Analysis Reports. Regional Patent Clustering in East Asia.
